Mutation of the -yc chain common to interleukin-2 (IL-2). IL-4, IL-7, IL-9, and IL-15 receptors has been shown to be responsible for the X chromosome-linked severe combined immune deficiency (SCIOXI). Human SClDXl patients are characterized by an absence of T and natural killer cell differentiation. We report the case of a SClDXl patient who first had few detectable peripheral T cells, then developed, after haploidentical T-depleted bone marrow transplantation (BMT), up to 2,0001pL autologous T cells. These T cells have persisted over 8 years after BMT and were able to proliferate in the presence of mitogens and of some antigens, although CHROMOSOME-linked severe combined immunodeficiency disease ( 
to a lesser extent than control T cells. A stop mutation was identified which predicts that the major part of the cytoplasmic tail of yc is truncated. This mutation does not affect high-affinity IL-2 binding, but it partly decreases IL-2 endocytosis and preventsthe downmodulation of the IL-2-receptor p chain and the tyrosine phosphorylation of Jak 3 protein in response to IL-2. This report raises questions concerning the role of the 'yc chain in IL-2 receptor endocytosis and in T-cell development and differentiation.
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and high-affinity (kd = 10 to 100 pmol/L) receptors contain IL-2RPyc or IL-2Ra,G, and IL-2Rapyc, respectively. The severity of SCIDXl results from the participation of the yc chain not only in the IL-2R complex but in multiple cytokine receptors including IL4R, IL-7R, IL-9R, and IL-15R."'~'' IL-2 signaling requires heterodimerization of IL-2RP and yL induced by IL-2 binding." This is followed by the phosphorylation and activation of multiple cellular substrates, principally of Jakl and Jak 3, associated to IL-2Ro and IL2Ry,, respectively, members of the Janus family of kinases.I3 Another early event is the rapid internalization of the multimolecular IL-2R in endocytic compartments.'"" The specific chains responsible for endocytosis of high-affinity IL-2R have not been fully elucidated, but IL-2Rp has been shown to be constitutively internalized, independently of IL-2R-y' .Ix
Mutations resulting in the SCIDXl phenotype are heterogeneous. Most of them were identified in the extracellular domain of IL-2RyC, and result in the loss of high-affinity IL-2R binding." A few mutations were identified within the cytoplasmic tail of IL-2RyC, and these alter the ability of IL-2R to associate with the tyrosine kinase Jak 3, thus interfering with signal transduction.5."
We report clinical, immunological, and genetic findings pertaining to a patient affected by a typical form of SCIDX 1, in whom a subnormal autologous T-cell population developed a few months after an allogenic BMT and persisted thereafter. Analysis of the functional consequences of the common -yc chain mutation on high-affinity IL-2 binding, endocytosis and downmodulation of the IL-2R may contribute to a better understanding of the precise role of the yL chain in cytokine receptor function.
PATIENT
The patient was the second child of a couple of Italian origin. His parents and older sister were healthy, and there was no history of disease in the family. Infections began at 1 month of age, when he developed protracted diarrhea with failure to thrive and repeated bronchopneumonitis. At diagnosis at 4 months of age, immunological investigations showed a T-cell lymphocytopenia (300 CD3' T cells/pL), a high B-cell count (2,370 CD19+ B cells/pL), and hypogammaglobulinemia. Adenosine deaminase activity was normal. There was no proliferation to phytohemagglutinin, nor was there detectable NK cell cytotoxicity. At 11 months of age, the patient underwent a T-depleted haploidentical BM transplant from his mother, without any conditioning regimen. T depletion of the BM was performed by E-rosetting and a total of 10' T cellskg were injected. During the 8 years following BMT, the patient had mild and repeated infections with mild failure to thrive (growth and weight, -2SD).
MATERIALS AND METHODS

Immunological Investigations
T-cell numeration was performed on whole blood using phycoerythrin (PE) conjugated anti-CD3 monoclonal antibody (MoAb) (Leu 4-Becton Dickinson, Mountain View, CA). Proliferation assays were performed on peripheral blood mononuclear cells (PBMC) stimulated either with the mitogen phytohemagglutinin (Difco, Detroit, MI) (final dilution 11700) for 3 days, or for 6 days with either candida antigen (2 pg1mL; Institut Pasteur, Paris, France) or tetanus toxoid (final dilution 11250; Institut Merieux, Lyon, France). In some experiments, recombinant IL-2 (Genzyme, Cambridge MA; 5 ng1mL) and anti-CD25 MoAb (BB10 Biotest, Germany; I pg/mL) were used. Proliferation was measured by 'H-Thymidine uptake.
DNA Analysis
Sequence analysis of the gene encoding the y,chain. Full length IL-2RyC chain transcripts were polymerase chain reaction (PCR)-amplified from a B-lymphoblastoid cell line (B-LCL) using reverse transcriptase (RT)-nested PCR and directly sequenced with 3zP endlabeled internal primers using a thermal cycler sequencing kit (New England Biolahs, Beverley, MA)." Sequences of the primers were previously reported.'" Exon 7 of the IL-2RyC gene were also amplified from genomic DNA of ST B-LCL and T cells by using flanking intronic primers2' and directly sequenced by the same method.
Search for chimerism, in the patient following BMT from the mother was performed on DNA isolated from patient E-rosettepositive (E') PB cells, E-rosette-negative (E-) PB cells and polymorphonuclear cells (PMN). PCR was performed on 1 pg of the DNA preparation using the primers ATT and AAT which detect a trinucleotide repeat polymorphism at the DXS 101 locus, as previously described." One tenth of each reaction mixture was analyzed on a 5% polyacrylamide 8 mol/L urea sequencing gel. In these conditions the sensitivity of chimerism detection was 0.1 %, in agreement with published data. To study IL-2Rp downregulation, exponentially growing cells were incubated at 2.106 cells1mL at 37°C for the indicated times with L 2 at specified concentrations. After two washes in cold phosphatebuffered saline (PBS), the cells were stained with anti-IL-2Rp antibodies for 60 minutes at 4°C. After one wash in cold PBS, they were labeled with the second antibody for 45 minutes at 4"C, washed once, and analyzed by cytofluorimetry.
Scatchard analysis and '"I-IL-2 endocytosis Pure recombinant IL-2 was obtained from SANOFI (Labege, France) and RousselUclaf (Romainville, France). IL-2 was radiolabeled with "' 1 by the chloramine T method to a specific activity of 30 to 100 X IOh cpm/ pg. Nonspecific binding of radiolabeled IL-2 was measured in the presence of a 500-fold molar excess of cold IL-2 and was subtracted. Scatchard analysis studies using '2SI-labeled IL-2 were performed as d e s~r i b e d , '~,~~, '~ and the data were fit by computer analysis. For endocytosis studies, B-cell lines were incubated in 1 0 0 pL RPMI-HEPES, pH 7.2, 10% FCS, with 150 pmol/L '2sI-labeled IL-2 for 1 hour at 4°C. At the end of the incubation, the cells were washed twice at 4°C to remove unbound ligand. The cells were then resuspended in the same medium at 37°C. Aliquots were removed at different times and rapidly cooled down to 4°C by adding 1 mL cold medium. Cell surface associated radioactive ligand was then removed by two successive acid pH treatments (2 minutes at pH 2 at 4°C) as previously d e s~r i b e d .~~ Nonspecific binding, measured for each ligand by adding a 500-fold excess of the same unlabeled ligand was subtracted. The efficiency of removal of cell-surface associated ligands by acid pH washes was measured for each ligand and was greater than 99%. The data presented here show specific binding and internalization.
Tyrosine kinase phosphorylation study. B-LCLs were procured, washed in RPMI 1640, and resuspended at a density of 20 X lo6/ mL in the same medium. They were then incubated at 37°C for I O minutes with 250 U1mL IL-2 (Genzyme, Cambridge, MA). Cell activation was stopped by incubation at 4°C and centrifugation. The cells were lysed for 30 minutes on ice in lysis buffer (20 mmol/L Tris, pH 7.5; 140 m m o K NaCI; 2 mmol/L EDTA; 50 mmol/L NaF 1 mmol/L Sodium orthovanadate; 1% [wt/vol] Nonidet P-40) to which the protease inhibitors antipah, pepstatin, leupeptin (each at 2 pg/mL), aprotinin (10 pglmL), and phenyl methylsulfonyl fluoride (1 mmol/L) were freshly added. Immunoprecipitations of precleared lysates were performed at 4°C overnight with the polyclonal antibody directed against the Jak 3 protein (Santa Cruz Biotechnology, Santa Cruz, CA). Immunoprecipitated proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membrane. Western blots were performed with antibodies against phosphotyrosine 4G10 (Upstate Biotechnology, Lake Placid, NY) and polyclonal antibodies against Jak 3 protein. Immunoreactive bands were visualized with the chemiluminescence Western blotting system (Amersham, Arlington Heights, IL).
RESULTS
Immunological time course study and chimerism afer BMT. The patient first presented a typical SCIDXl phenotype with an immunodeficiency characterized by panhypogammaglobulinemia, lymphocytopenia with a very low Tcell count and an elevated B-cell count, and the absence of proliferation to mitogens and antigens. At 11 months of age, he received a depleted haploidentical BMT from his mother. At 14 months of age, a rise in the CD3+ lymphocyte count was detected, which subsequently persisted during the following years (900 to 2,8OO/pL) (Fig 1) . This population contained mature-phenotype CD4' or CD8' T cells. How- ever, a progressive decrease of the CD4' T-lymphocyte count occurred from 32 months of age (700/pL) until now (300/pL), whereas the CD8' lymphocyte count did not change over time (around l,lOO/pL). Simultaneously, the Bcell count decreased from 580/mL before BMT to 40/mL 7 years later (not shown). Mitogen-induced T-cell proliferation, initially negative at 4 and 9 months of age, became positive 5 months after BMT, and remained positive during the seven following years (Table 1) . Similarly, T cells were able to proliferate in response to tetanus toxoid and candida antigens after BMT, although the responses rarely reached normal values (Table l ) . To study the role of the IL-R complex in the proliferation of the patient's T cells in response to antigens, either soluble IL-2 or anti-IL-2Ra antibody was added to the culture. As shown in Table 2 , antigen mediated response of patient's and control's cells was enhanced when IL-2 was added. Also, the anti-IL-2Ra antibody BB10 inhibited the proliferation in response to antigens of both patient's and control cells.
Chimerism was repeatedly analyzed from 3 months to 7 years after BMT by using different methods. HLA typing of recipient T and B cells was performed by serotyping 3 months after BMT and by single strand conformational poly-MORELON ET AL morphism (SSCP) allele-specific PCR on E' and E-cells, 7 years later. The sensitivity of the latter method is sufficient to detect between 1/5,000 and 1/10,000 cells. Both methods showed that these cells had exclusively the patient HLA phenotype (data not shown). Karyotype analysis on Erosette' PB cells, performed 9 and 16 months after BMT, showed that 100% of the cells studied were XY (data not shown). DNA haplotype analysis using the polymorphic trinucleotide repeat DXSIOI X chromosome marker was performed on distinct circulating hematopoietic cell populations of the patient and of his mother, 21 months following BMT.
As shown in Fig 2, a unique allele is detected at DXSIOI locus in the patient's cell populations, including the T-cell subset, whereas two alleles are detected in his mother's cell populations. These results show the presence of an autologous T-cell population in the patient following allogenic BMT, and the absence of detectable peripheral cells from maternal origin.
In conclusion, donor cells were not detectable after BMT, indicating that the mother's BM did not engraft and that the patient had autologous BM reconstitution with development of partially functional T cells.
IL-ZRy, gene mutation in the patient. Because of the typical XSCID phenotype presented by the patient before BMT, we analyzed the IL-2Ryc transcript of the patient's B-LCL by direct sequencing of the PCR amplified product. A single point mutation was detected in the patient's IL2Ry, gene consisting of a C to T base transition at position 865 in exon 7, corresponding to amino acid 289 and replacing the normal arginine-encoding codon by a premature stop codon (not shown). The mutation was also detected by sequencing genomic DNA from B-LCL and T cells (Fig 3) . This transition results in a predicted protein lacking 81 amino acids at the carboxy terminus (Fig 3) . We have immunoprecipitated IL-2Ryc from control B-LCL, the patient B-LCL, IL-2Ryc-B-LCL, and from YT cells. By western blotting with an antiserum directed against a peptide corresponding. to amino-acid 342-361 mapping at the carboxy terminus of IL-2RyC, the presence of IL-2Ryc was clearly detected in YT cells and control B-LCL, wheras no IL-2RyC could be observed with ST cells or IL-2Ryc-cells, in agreement with the predicted truncation shown by the DNA analysis.
We have checked that no secondary mutation was present on the patient's T cells. This study was performed twice at 5 years interval by SSCP analysis and by direct sequencing For of DNA isolated from the patient's E-rosette+ PB cells (containing more than 95% T lymphocytes). The DNA sequence obtained from the patient's T cells was exactly the same, in the 2 samples taken at 5 years interval, as the DNA sequence obtained from his B-LCL (Fig 3) . This rules out the possibility that there may exist a second corrective genetic change in the T-cell population altering the SCIDXI phenotype. Sequence analysis of the same region IL-2RyC transcript of the patient's mother did not detect any mutations, indicating that the mutation occurred de novo. Surface expression of IL-ZRP and IL-ZRy,, We next determined whether the IL-2RP and IL-2RyC chains were expressed on the cell surface of the patient's lymphoid cells. We studied the expression of the IL-2RP and IL-2RyC chains on the patient's EBV-transformed B-LCLs. This EBV transformed cell line will be referred to as ST from now on.
Previous studies have shown that EBV-transformed human B cells express both high-and low-affinity IL-2R, indicating the presence of IL-2Ra, P, and yc chains. both IL-2RP and IL-2RyC. The level of expression of IL2Ry, and IL-2RP was similar in ST and in control cells. In contrast, no yF chain expression was detectable in the B-cell line of a SCIDXI patient in whom a genomic deletion of the yc gene has been identified (Fig 4) .
ST cells express high-afJinity IL-2R. Because IL-2RP and yc were expressed on the cell surface of ST cells, we next determined if the truncated form of IL-2RyC expressed in this patient was capable of associating with the other IL-2R components to form high-affinity receptors. Three different affinity IL-2Rs can be formed by association of the IL- In ST cells, Scatchard analysis showed that IL-2 binding was due to high-affinity IL-2R composed of the three chains. Therefore, the IL-2RyC mutation of ST does not affect the formation and ligand binding properties of high-affinity IL-2R.
IL-2 endocytosis by ST cells. One of the early events following IL-2 binding to high-affinity receptors is ligand and receptor endocyto~is.'~.'' Because the cytoplasmic tail of IL-2RyC is mostly deleted in ST cells, we asked how this intracellular deletion affects IL-2 endocytosis. ST cells having bound "sI-IL-2 at 4°C were washed and transfered to 37"C, and the kinetics of IL-2 internalization were analyzed. I2'I-IL-2 was internalized in ST cells (Fig 6) . However, it was internalized less efficiently than in control cells because a 50% reduction was observed. Therefore, although most of the intracellular IL-2RyC region is absent, IL-2 can still be internalized, but not as well as when IL-2RyC is intact.
Downmodulation of IL-2R in ST cells. We have previously shown that IL-2 high-affinity receptors are constitutively internalized in the absence of ligand and that IL-2 increases their endocytosis rate by a factor of Thus, IL-2 induces high-affinity receptor downregulation. Because high-affinity receptors are composed of three noncovalently linked chains, downregulation of only one chain should be sufficient to cause downregulation of the whole receptor. We know that IL-2RP is constantly internalized without ligand in T, B, and NK cell lines." Therefore, we analyzed the effect of IL-2 on IL-2RP surface expression both in T and B cell lines expressing high-affinity receptors (IL-2Rq p, and y c ) .
As seen in Fig 7B and C, IL-2 induces IL-2Rp downregulation in both T-and B-cell lines expressing high-affinity receptors (IL-2Ra, p, and ?=). Downregulation of IL-2RP is also observed in the NK YT cell line expressing only intermediate affinity receptors (IL-2RP and y c ) (Fig 7D) .
However, IL-2Rp downregulation could not be observed in ST cells expressing the truncated IL-2RyC (Fig 7A) . We have shown that IL-2 induced receptor downregulation is caused by an increase in the net rate of receptor internalizat i~n .~~ Therefore, sequences missing in this patient's IL-2RyC are necessary for IL-2RP downmodulation.
Absence of Jak3 tyrosinephosphorylation in STcells. Tyrosine phosphorylation of the Janus Kinase proteins is one of the early biochemical events which follows IL-2 stimulation. The protein kinase Jak 3 is phosphorylated in response to cytokines whose receptors contain the y c chain (L-2, L-4, IL-7, and IL-9)." Furthermore, Jak 3 is physically associated with the cytoplasmic domain of the yc chain. Based on transfection studies in COS cells, it has been reported that this association requires the presence of the 48 COOH terminal aminoacids.13 Jak 3 has been recently shown to play a key role in T-cell differentiation and activation in h~mans.~'.~' Given the phenotype of the patient, we examined whether Jak 3 might be tyrosine phosphorylated on IL-2 stimulation of the endogenous IL-2R in ST cells. As shown in Fig 8 immunoprecipitation with antibody to J a k 3 yielded a tyrosine phosphorylated band in response to L -2 in control B-LCL, but no band was detected in ST cells. When the filter was stripped and reprobed with antiJak 3 antibody, equivalent amounts of Jak 3 were precipitated in each case. Therefore, as expected, Jak 3 was not phosphorylated in ST patient in response to IL-2.
DISCUSSION
We report the case of an atypical SCIDXl patient who had a mature peripheral T-cell population even though the cells expressed a yc chain missing most of the cytosolic tail. of the intracellular tail of IL-2RyC would thus be to accelerate receptor entry. Two mechanisms can be proposed to explain the role of IL-2RyC. The first is that each of the chains, IL-2RP and y c , carries its own endocytic signal: when the heterodimer is formed, both signals function in an additive way, increasing the rate of entry. Such a mechanism has been described for the transferrin receptor when two endocytic signals were introduced in its cytoplasmic tail. 34 The second hypothesis concerns phosphorylation events induced by IL-2, which are mediated by the association of the cytoplasmic tails of IL-2RP and y c with tyrosine kinases, such as those of the JANUS family." Phosphorylation may modify the rate of IL-2R endocytosis, as described for EGF receptor^.^^.^^ Recent studies based on Jak3, IL-7Rq IL-7, and yc knockout r n i~e~~.~" and on SCID patients with mutations in Jak3 part of the IL-7R in T-cell development and for the Jak3 signaling pathway. Although ST IL-2RyC truncation does not affect IL-2 high-affinity binding and partly decreases endocytosis, it dramatically affects the Jak3 signaling pathway. The presence in patient ST of an autologous T-cell population with partially preserved functions suggests that y,-independent cytokines or other signaling pathways allow some T-cell differentiation and function to occur. The recently identified IL-7-like cytokine termed "thymic stromal-derived lymphopoietin"38 could account for such a mechanism. In addition, a cytokine combination that excluded IL-7 allowed in vitro T-cell development from pro-T cells.4' In this regard, one could hypothesize that the haploidentical BM transplant provided a cytokine that could substitute for IL-7 in supporting early T-cell development. However, none of the cell populations tested in the patient were from the donor, and BMT performed in a number of SCIDXl patients were never reported to induce autologous T-cell reconstituti~n!~.~~ Although the truncated y E molecule in the ST patient have lost the ability to mediate Jak3 phosphorylation, one cannot conclude that ST y c is completely nonfunctional. IL-2R are not downmodulated by IL-2, and their constant expression may favor alternative signaling pathways. Indeed, multiple cellular substrates besides the Janus kinase family were shown to be activated in response to IL-2."-'8 The results observed in the ST patient suggest that the functions of the cytoplasmic region of y c , whether in the context of the IL-2R or any of the other receptors sharing the yc chain, may be partially bypassed during the development of a mature T-cell population in humans.
Although most of the mutations described so far in SCIDXI patients are localized in the extracellular or transmembrane region of the yc chain, few mutations were found in the cytosolic tail. In three previously described patients, the same nonsense mutation as found in the ST patient has been thus identifying a hot-spot for mutations. In two other patients, stop-mutations further downstream were identified.',@' The few clinical studies concerning these patients do not report the precise levels of circulating T cells, but they are reported as typical SCIDXl patients, and no data from follow-up studies are available.
The relatively late age of the patient at the time of BMT or in yc 5.31.32 show a critical nonredundant role for yc as may also be one of the variables that influence the appearance of peripheral T cells. It is worth noting that, in two unrelated families, the SCIDXI patients previously described with a leaky phenotype displayed a T-cell lymphocytopenia during the first months of life.6'.62 The peripheral Tcell counts became normal later, although with a restricted repertoire,20363 which may partly explain the impaired T-cell functions observed. A restricted T-cell repertoire cannot be excluded in patient ST. Different genetic backgrounds may also account for heterogeneous expression of SCIDXI, as already reported within some XLA families, where considerable phenotypic heterogeneity can be Species-species differences in SCIDXl have been well-documented: the IL-2RyC-deficient mice4' and SCIDXl dogs" develop some mature B and T cells, although they are not functional, and considerable variation of T-cell numbers among affected dogs has been n~ticed.~' In this respect, they differ from the typical form of SCIDXl described in humans, but not from the patient reported here or the two other patients with a mild form of SCIDXl already de~cribed!~.~~ Patient ST differs from the mouse and canine SCICX model, in which the y c gene is either deleted4' or not expressed on the surface due to a microdeletion very early in the coding region.% However, the recent observation that yc mutant mice with a truncated yc cytoplasmic tail display a similar phenotype to that of the null mutant in terms of development of lymphocyte populations68 suggests that the truncated y c in patient ST might not play a dominant role in the T-cell differentiation observed.
It is likely that the diagnostic criteria of SCIDXl based on the absence of circulating T cells, may have led to misdiagnosis of a number of SCIDXl patients with an "atypical" phenotype. Molecular studies of IL-2RyC should now allow detection of patients having phenotypes closer to the one of the ST patient. Similar to what has been described in animal models, it thus appears that the absence of a functional y c chain in humans does not necessarily lead to a severe block in T-cell differentiation and that, in certain circumstances, alternative pathways may partly overcome the y c chain defect to allow some T-cell differentiation and function, even if a severe immune deficiency persists.
